Diamel therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, and hyperandrogenaemia
- PMID: 22778733
- PMCID: PMC3388435
- DOI: 10.1155/2012/382719
Diamel therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, and hyperandrogenaemia
Abstract
For to determine the effect of Diamel on the insulin resistance, insulin sensitivity, and sexual hormones results in women with polycystic ovary syndrome (PCOS). A study was carried out on 37 patients with this disorder. A triple-blind clinical trial was designed in which the Diamel food supplement was compared with a placebo. The women with reproductive ages were randomly distributed in two groups, with 18 and 19 women respectively, and they took Diamel or placebo and were followed up during 6 months with clinical and biochemical evaluation. A significant decrease in the HOMA-IR from the initial value at six months was observed in the group with Diamel. The insulin sensitivity improved considerably in this group. The rate of menstrual recovery was higher in the group with Diamel, and two patients from this group obtained pregnancy. The hormone levels shows a significant decrease in testosterone at 3 months in the group with Diamel compared with the control group. The LH also decreases in the same group when comparing the start with 6 months.We concluded that the Diamel decreases insulin resistance and improves sensitivity to this hormone in women with PCOS, with improvement in the levels of LH and testosterone.
Similar articles
-
Effect of hyperinsulinaemia and insulin resistance on endocrine, metabolic and fertility outcomes in women with polycystic ovary syndrome undergoing ovulation induction.Clin Endocrinol (Oxf). 2019 Sep;91(3):440-448. doi: 10.1111/cen.14050. Epub 2019 Jun 28. Clin Endocrinol (Oxf). 2019. PMID: 31222771 Clinical Trial.
-
Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.Gynecol Endocrinol. 2007;23(8):461-7. doi: 10.1080/09513590701492689. Gynecol Endocrinol. 2007. PMID: 17852414
-
Effect of Diamel in patients with metabolic syndrome: a randomized double-blind placebo-controlled study.J Diabetes. 2013 Jun;5(2):180-91. doi: 10.1111/1753-0407.12007. J Diabetes. 2013. PMID: 22978615 Clinical Trial.
-
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.Adv Ther. 2021 Jul;38(7):3842-3856. doi: 10.1007/s12325-021-01789-5. Epub 2021 May 28. Adv Ther. 2021. PMID: 34047916 Clinical Trial.
-
Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.Fertil Steril. 1996 Jul;66(1):54-60. doi: 10.1016/s0015-0282(16)58387-3. Fertil Steril. 1996. PMID: 8752611 Clinical Trial.
Cited by
-
Antioxidants for female subfertility.Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD007807. doi: 10.1002/14651858.CD007807.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Aug 27;8:CD007807. doi: 10.1002/14651858.CD007807.pub4. PMID: 28752910 Free PMC article. Updated.
-
Antioxidants for female subfertility.Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD007807. doi: 10.1002/14651858.CD007807.pub4. Cochrane Database Syst Rev. 2020. PMID: 32851663 Free PMC article.
References
-
- Carvajal R, Herrera C, Porcile A. Espectro fenotípico del síndrome de ovarios poliquísticos. Revista Chilena de Obstetricia y Ginecología. 2010;75(2):124–132.
-
- Marsden PJ, Murdoch AP, Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clinical Endocrinology. 2001;55(2):191–199. - PubMed
-
- Clayton RN, Ogden V, Hodgkinson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clinical Endocrinology. 1992;37(2):127–134. - PubMed
-
- Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology. 2004;60(1):1–17. - PubMed
-
- Nestler JE. Insulin and ovarian androgen excess. In: Azziz R, Nestler JE, Denally D, editors. Androgen Excess Disorders in Women. Philadelphia, Pa, USA: Lippencott-Raven; 1997. pp. 473–483.
LinkOut - more resources
Full Text Sources